Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,973
datasets available to search
ShareScore release 0.9.0
Dataset results
1,973 results for “T cell receptor”
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
ClinicalTrials.gov study NCT06939166. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy
ClinicalTrials.gov study NCT07266181. IPD Sharing: Not stated. Countries: 1. Publications: 0.
D2 Dopamine Receptor on Human Aldosterone-Producing Adenoma and Its Role in Aldosterone Secretion and Cell Proliferation
ClinicalTrials.gov study NCT00173446. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors
ClinicalTrials.gov study NCT05393986. IPD Sharing: NO. Countries: 1. Publications: 0.
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
ClinicalTrials.gov study NCT05680922. IPD Sharing: NO. Countries: 1. Publications: 0.
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
ClinicalTrials.gov study NCT03938987. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cu
ClinicalTrials.gov study NCT07055477. IPD Sharing: YES. Countries: 1. Publications: 0.
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
ClinicalTrials.gov study NCT04650724. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
ClinicalTrials.gov study NCT02813837. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
ClinicalTrials.gov study NCT01221077. IPD Sharing: NO. Countries: 6. Publications: 0.
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03943472. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exo
ClinicalTrials.gov study NCT04576208. IPD Sharing: YES. Countries: 0. Publications: 0.
VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC)
ClinicalTrials.gov study NCT02103179. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
ClinicalTrials.gov study NCT06568328. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
ClinicalTrials.gov study NCT05442515. IPD Sharing: YES. Countries: 1. Publications: 0.
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
ClinicalTrials.gov study NCT06478251. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL
ClinicalTrials.gov study NCT04206943. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Relationship Between Maternal Soluble Trigger Receptor Expressed on Myeloid Cells-1 (sTREM-1) and Placenta Accreta Spectrum
ClinicalTrials.gov study NCT05376410. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Analysis of Soluble TREM (Triggering Receptor Expressed on Myeloid Cells)-1 and -2 in Crevicular Fluid and Associated Bacterial Flora in Patients Affected by Periodontitis
ClinicalTrials.gov study NCT02873949. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Ma
ClinicalTrials.gov study NCT05836896. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.